Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
68.79
+1.08 (1.60%)
Jun 2, 2025, 4:00 PM - Market closed

Haemonetics Statistics

Total Valuation

Haemonetics has a market cap or net worth of $3.30 billion. The enterprise value is $4.28 billion.

Market Cap 3.30B
Enterprise Value 4.28B

Important Dates

The last earnings date was Thursday, May 8, 2025, before market open.

Earnings Date May 8, 2025
Ex-Dividend Date n/a

Share Statistics

Haemonetics has 48.04 million shares outstanding. The number of shares has decreased by -1.30% in one year.

Current Share Class 48.04M
Shares Outstanding 48.04M
Shares Change (YoY) -1.30%
Shares Change (QoQ) -2.30%
Owned by Insiders (%) 0.99%
Owned by Institutions (%) 115.25%
Float 47.54M

Valuation Ratios

The trailing PE ratio is 20.78 and the forward PE ratio is 14.12. Haemonetics's PEG ratio is 0.99.

PE Ratio 20.78
Forward PE 14.12
PS Ratio 2.54
Forward PS 2.47
PB Ratio 4.04
P/TBV Ratio n/a
P/FCF Ratio 23.20
P/OCF Ratio 18.18
PEG Ratio 0.99
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.02, with an EV/FCF ratio of 30.04.

EV / Earnings 25.52
EV / Sales 3.14
EV / EBITDA 12.02
EV / EBIT 17.32
EV / FCF 30.04

Financial Position

The company has a current ratio of 1.62, with a Debt / Equity ratio of 1.56.

Current Ratio 1.62
Quick Ratio 0.88
Debt / Equity 1.56
Debt / EBITDA 3.49
Debt / FCF 9.01
Interest Coverage 6.88

Financial Efficiency

Return on equity (ROE) is 18.83% and return on invested capital (ROIC) is 7.84%.

Return on Equity (ROE) 18.83%
Return on Assets (ROA) 6.65%
Return on Invested Capital (ROIC) 7.84%
Return on Capital Employed (ROCE) 13.19%
Revenue Per Employee $450,157
Profits Per Employee $55,468
Employee Count 3,023
Asset Turnover 0.59
Inventory Turnover 1.71

Taxes

In the past 12 months, Haemonetics has paid $44.39 million in taxes.

Income Tax 44.39M
Effective Tax Rate 20.93%

Stock Price Statistics

The stock price has decreased by -18.19% in the last 52 weeks. The beta is 0.32, so Haemonetics's price volatility has been lower than the market average.

Beta (5Y) 0.32
52-Week Price Change -18.19%
50-Day Moving Average 63.87
200-Day Moving Average 72.27
Relative Strength Index (RSI) 59.66
Average Volume (20 Days) 588,330

Short Selling Information

The latest short interest is 4.08 million, so 8.48% of the outstanding shares have been sold short.

Short Interest 4.08M
Short Previous Month 4.43M
Short % of Shares Out 8.48%
Short % of Float 8.57%
Short Ratio (days to cover) 6.83

Income Statement

In the last 12 months, Haemonetics had revenue of $1.36 billion and earned $167.68 million in profits. Earnings per share was $3.31.

Revenue 1.36B
Gross Profit 778.55M
Operating Income 247.10M
Pretax Income 146.99M
Net Income 167.68M
EBITDA 355.99M
EBIT 247.10M
Earnings Per Share (EPS) $3.31
Full Income Statement

Balance Sheet

The company has $308.07 million in cash and $1.28 billion in debt, giving a net cash position of -$975.28 million or -$20.30 per share.

Cash & Cash Equivalents 308.07M
Total Debt 1.28B
Net Cash -975.28M
Net Cash Per Share -$20.30
Equity (Book Value) 820.84M
Book Value Per Share 17.02
Working Capital 356.86M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $181.73 million and capital expenditures -$39.28 million, giving a free cash flow of $142.45 million.

Operating Cash Flow 181.73M
Capital Expenditures -39.28M
Free Cash Flow 142.45M
FCF Per Share $2.97
Full Cash Flow Statement

Margins

Gross margin is 57.21%, with operating and profit margins of 18.16% and 12.32%.

Gross Margin 57.21%
Operating Margin 18.16%
Pretax Margin 15.58%
Profit Margin 12.32%
EBITDA Margin 26.16%
EBIT Margin 18.16%
FCF Margin 10.47%

Dividends & Yields

Haemonetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield 1.30%
Shareholder Yield 1.30%
Earnings Yield 5.07%
FCF Yield 4.31%
Dividend Details

Analyst Forecast

The average price target for Haemonetics is $99.78, which is 45.05% higher than the current price. The consensus rating is "Strong Buy".

Price Target $99.78
Price Target Difference 45.05%
Analyst Consensus Strong Buy
Analyst Count 9
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.

Last Split Date Dec 3, 2012
Split Type Forward
Split Ratio 2:1

Scores

Haemonetics has an Altman Z-Score of 2.75 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.75
Piotroski F-Score 5